|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
|
FI884924A7
(fi)
|
1987-10-28 |
1989-04-29 |
Oncogen |
Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
|
|
US5151504A
(en)
|
1989-11-17 |
1992-09-29 |
E. R. Squibb & Sons, Inc. |
Method for purification of monoclonal antibodies
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
CA2111858A1
(en)
|
1991-07-15 |
1993-02-04 |
James S. Crowe |
Production of antibodies
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
CN100457914C
(zh)
|
1999-04-15 |
2009-02-04 |
荷兰克鲁塞尔公司 |
用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
|
|
US20070111201A1
(en)
|
2001-04-30 |
2007-05-17 |
Benjamin Doranz |
Reverse transfection of cell arrays for structural and functional analyses of proteins
|
|
ATE466941T1
(de)
|
2001-07-04 |
2010-05-15 |
Chromagenics Bv |
Dns-sequenzen mit anti-repressor-aktivität
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
WO2003107218A1
(ja)
|
2002-05-31 |
2003-12-24 |
セレスター・レキシコ・サイエンシズ株式会社 |
相互作用予測装置
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
ES2273202T3
(es)
|
2003-01-07 |
2007-05-01 |
Symphogen A/S |
Procedimiento para producir proteinas policlonales recombinantes.
|
|
NZ543635A
(en)
|
2003-06-25 |
2008-05-30 |
Crucell Holland Bv |
Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
|
|
CN1997382A
(zh)
|
2004-05-05 |
2007-07-11 |
梅里麦克制药股份有限公司 |
调节生物活性的双特异性结合剂
|
|
JP5139800B2
(ja)
|
2004-06-03 |
2013-02-06 |
ノビミューン エスアー |
抗ｃｄ３抗体およびその使用方法
|
|
EP1789446A2
(en)
|
2004-09-02 |
2007-05-30 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CA2599606A1
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
US20060212956A1
(en)
|
2005-03-14 |
2006-09-21 |
Genentech, Inc. |
Animal model of ligand activated HER2 expressing tumors
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
US8871912B2
(en)
|
2006-03-24 |
2014-10-28 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
|
US8290739B2
(en)
|
2006-10-20 |
2012-10-16 |
Amfit, Inc. |
Method for determining relative mobility of regions of an object
|
|
AU2007353412A1
(en)
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
|
SG178789A1
(en)
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
WO2008119566A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
US7705103B2
(en)
|
2007-06-22 |
2010-04-27 |
3M Innovative Properties Company |
Polydiorganosiloxane polyoxamide copolymers
|
|
DK2173379T3
(en)
|
2007-07-02 |
2015-12-07 |
Oncomed Pharm Inc |
Compositions and methods for treatment and diagnosis of cancer
|
|
EP2211903A4
(en)
|
2007-10-17 |
2011-07-06 |
Nuvelo Inc |
CLL-1 ANTIBODY
|
|
CA2711843C
(en)
|
2007-12-20 |
2018-11-13 |
Laboratory Corporation Of America Holdings |
Her-2 diagnostic methods
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
EP2245571B1
(en)
|
2008-02-05 |
2019-04-10 |
Zymeworks Inc. |
Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
|
|
PL3456190T3
(pl)
|
2008-06-27 |
2022-06-06 |
Merus N.V. |
Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
|
|
US8663640B2
(en)
|
2008-08-29 |
2014-03-04 |
Symphogen A/S |
Methods using recombinant anti-epidermal growth factor receptor antibody compositions
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
SG172983A1
(en)
|
2009-01-15 |
2011-08-29 |
Lab Corp America Holdings |
Methods of determining patient response by measurement of her-3
|
|
US20120020952A1
(en)
|
2009-01-26 |
2012-01-26 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
JP5752687B2
(ja)
|
2009-08-21 |
2015-07-22 |
メリマック ファーマシューティカルズ インコーポレーティッド |
Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2496598B1
(en)
|
2009-11-04 |
2017-08-02 |
Affibody AB |
Her3 binding polypeptides
|
|
CN102666585B
(zh)
|
2009-11-24 |
2015-02-18 |
阿莱斯亚生物疗法股份有限公司 |
抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
|
|
SI2501817T2
(sl)
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US20130185821A1
(en)
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
PL2606064T3
(pl)
|
2010-08-16 |
2015-07-31 |
Novimmune Sa |
Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
|
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
EP2678359A4
(en)
|
2011-02-24 |
2015-01-28 |
Merrimack Pharmaceuticals Inc |
COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
SG192775A1
(en)
|
2011-03-15 |
2013-09-30 |
Merrimack Pharmaceuticals Inc |
Overcoming resistance to erbb pathway inhibitors
|
|
US9683052B2
(en)
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
NO2707391T3
(https=)
|
2011-05-13 |
2018-04-07 |
|
|
|
AU2012274461A1
(en)
|
2011-06-20 |
2014-01-16 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-erbB3 antibody
|
|
US9567827B2
(en)
|
2013-07-15 |
2017-02-14 |
Downhole Technology, Llc |
Downhole tool and method of use
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
HK1200468A1
(en)
|
2011-09-30 |
2015-08-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
JP6180425B2
(ja)
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
EA201491120A1
(ru)
|
2011-12-05 |
2015-07-30 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
WO2013134686A1
(en)
|
2012-03-09 |
2013-09-12 |
Promega Corporation |
pH SENSORS
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
SI2838917T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
|
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗－ｅｇｆｒ抗體及其用途
|
|
EP3470431A1
(en)
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
|
CA2883264A1
(en)
|
2012-10-15 |
2014-04-24 |
Universitat Zurich Prorektorat Mnw |
Bispecific her2 ligands for cancer therapy
|
|
CN113201073A
(zh)
|
2012-11-21 |
2021-08-03 |
詹森生物科技公司 |
双特异性EGFR/c-Met抗体
|
|
JP2016510411A
(ja)
|
2013-02-04 |
2016-04-07 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
|
|
BR112015023074A2
(pt)
|
2013-03-14 |
2017-11-21 |
Oncomed Pharm Inc |
agentes de ligação-met e uso dos mesmos
|
|
WO2014165855A1
(en)
|
2013-04-05 |
2014-10-09 |
Laboratory Corporation Of America Holdings |
Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
US11229711B2
(en)
|
2013-06-06 |
2022-01-25 |
Magenta Therapeutics, Inc. |
Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
EP3030577B1
(en)
*
|
2013-08-07 |
2019-10-02 |
Universität zu Köln |
Novel nrg1 fusion genes in cancer
|
|
US9551208B2
(en)
|
2013-08-26 |
2017-01-24 |
Halliburton Energy Services, Inc. |
Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
|
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
|
US10813952B2
(en)
|
2014-11-14 |
2020-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
|
|
MA41123A
(fr)
|
2014-12-02 |
2017-10-10 |
Oncomed Pharm Inc |
Polythérapie pour le traitement du cancer
|
|
US11186875B2
(en)
|
2015-06-12 |
2021-11-30 |
The Translational Genomics Research Institute |
Targeted therapies for cancer
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
US20200291130A1
(en)
|
2017-03-31 |
2020-09-17 |
Merus N.V. |
Antibodies for the treatment of erbb-2/erbb-3 positive tumors
|
|
AU2018246873B2
(en)
|
2017-03-31 |
2021-05-06 |
Merus B.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
|
|
WO2018212656A1
(en)
|
2017-05-17 |
2018-11-22 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
CN118580366A
(zh)
|
2017-08-09 |
2024-09-03 |
美勒斯公司 |
结合EGFR和cMET的抗体
|